News

Fierce Biotech7h
Amgen rolls out ph. 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
BioPharma Dive5h
New Amgen obesity drug data disappoint Wall Street
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
STAT1d
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
Applied Clinical Trials Online7h
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...
Ozempic and Mounjaro have new competitor as trial sees people lose 20% of body weight in one year
The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...
What’s Happening With Amgen Stock?
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
New once-a-month drug could treat diabetes and obesity, scientists say
New once-a-month drug could treat diabetes and obesity, scientists say - Researchers say experimental drug’s less frequent ...